AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/17/23

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced voting results for its annual general meeting (the “Meeting”) of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to th...

2023-05-11 14:02:17 ET The largest shareholder of Aurinia Pharmaceuticals ( NASDAQ: AUPH ) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% stake, said it plans to withhold support from seven board ...

First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin) Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up ...

2023-05-04 13:08:04 ET Start Time: 08:30 End Time: 09:27 Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR ...

2023-05-04 07:48:27 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) shares spiked in the pre-market Thursday after the Canadian biotech posted a strong revenue beat with its Q1 2023 financials and increased its outlook for 2023 amid a strong uptake for its lupus nephritis therapy Lupkyn...

2023-05-04 06:03:45 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q1 GAAP EPS of -$0.18 beats by $0.04 . Revenue of $34.41M (+59.1% Y/Y) beats by $6.29M . As of March 31, 2023, Aurinia had cash, cash equivalents and restricted cash and short-term investment...

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS Significant progress across Commercial, R&D and Intellectual ...

2023-05-03 15:01:12 ET Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $28.12M (+30.0% Y/Y). Over the last 3 months, EPS es...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including ...

2023-05-03 03:10:35 ET Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021 the Company introduced the first FDA-approved oral therapy...